Literature DB >> 3128477

Development and characterization of an anti-idiotype antibody to the capsular polysaccharide of Neisseria meningitidis serogroup C.

M A Westerink1, A A Campagnari, M A Wirth, M A Apicella.   

Abstract

A monoclonal anti-idiotypic antibody (Ab2) whose antibody combining site contained a surrogate image of the meningococcal group C capsular polysaccharide was developed. To accomplish this, a monoclonal antibody against the group C capsular polysaccharide was developed by the fusion of splenocytes from mice immunized with Neisseria meningitidis group C strain MP13 with Sp2/0-Ag14 plasmacytoma cells. Monoclonal antibody 1E4, an immunoglobulin M isotype, demonstrated binding to the serogroup C polysaccharide in enzyme-linked immunosorbent assay (ELISA). Monoclonal antibody 1E4 reacted with 30 of 30 group C strains and 1 of 36 group B strains in immunodot assay, slide agglutination, inhibition ELISA, and bactericidal assay. This monoclonal antibody was selected as idiotype (Ab1) for the development of hybridomas producing an anti-idiotype antibody. One of the hybridomas developed, designated 6F9, was capable of over 70% inhibition of 1E4 in binding in the meningococcal C polysaccharide-specific ELISA. Studies with convalescent human serum demonstrated 100% inhibition of a serogroup C-specific ELISA with 200 micrograms of 6F9 per ml and 50% inhibition of this ELISA was achieved with 50 micrograms of 6F9 per ml. Monoclonal anti-idiotype antibodies (Ab3) with specificities similar to Ab1, 1E4 were generated from BALB/c mice immunized with the Ab2 (6F9). Immunization of rabbits with 6F9 resulted in an immunoglobulin G response which was significantly greater than that of control to a titer of 1:160. These studies indicate that monoclonal 6F9 contained a surrogate image on the combining antibody site which mimicked meningococcal C polysaccharide. This surrogate image is capable of evoking antibodies to the meningococcal C polysaccharide in syngenic and xenogenic species.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128477      PMCID: PMC259772          DOI: 10.1128/iai.56.5.1120-1127.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  New Classification of Neisseria meningitidis by Means of Bactericidal Reactions.

Authors:  R Gold; F A Wyle
Journal:  Infect Immun       Date:  1970-05       Impact factor: 3.441

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Idiotypic networks and their possible exploitation for manipulation of the immune response.

Authors:  I M Roitt; A Cooke; D K Male; F C Hay; G Guarnotta; P M Lydyard; L P de Carvalho; Y Thanavala; J Ivanyi
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

4.  Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland.

Authors:  P H Mäkelä; H Peltola; H Käyhty; H Jousimies; O Pettay; E Ruoslahti; A Sivonen; O V Renkonen
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

5.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

6.  Antigenic heterogeneity of the non-serogroup antigen structure of Neisseria gonorrhoeae lipopolysaccharides.

Authors:  M A Apicella; N C Gagliardi
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

7.  Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.

Authors:  H Peltola; H Käyhty; A Sivonen; H Mäkelä
Journal:  Pediatrics       Date:  1977-11       Impact factor: 7.124

Review 8.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

9.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  5 in total

1.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

2.  Meningococcal infections--what's next?

Authors:  A L Smith
Journal:  West J Med       Date:  1989-01

Review 3.  Anti-idiotypic antibodies as vaccines against carbohydrate antigens.

Authors:  M A Westerink; M A Apicella
Journal:  Springer Semin Immunopathol       Date:  1993

4.  Peptide mimicry of the meningococcal group C capsular polysaccharide.

Authors:  M A Westerink; P C Giardina; M A Apicella; T Kieber-Emmons
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

5.  An anti-idiotype antibody which mimics the inner-core region of lipopolysaccharide protects mice against a lethal challenge with endotoxin.

Authors:  S K Field; D C Morrison
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.